Oceanium Expands Board with Appointment of Sybille Buchwald-Werner, PhD

Oceanium, a UK-based seaweed biotechnology firm, recently announced the appointment of Sybille Buchwald-Werner, PhD, as a Non-Executive Board Member, effective January 22, 2026. With this appointment, Oceanium aims to reinforce its position as an investor-ready business, a press release from Oceanium explains.¹

A Strategic Addition of Industry Expertise

A scientist by training, Buchwald-Werner has more than 25 years of experience across pharmaceutical science, ingredient innovation, governance, and international commercialization, along with an entrepreneur record. She founded and scaled Vital Solutions GmbH into a globally recognized business before its successful acquisition in 2023. Currently, she leads Newday, a platform dedicated to translating scientific insights into strategies that drive business value and environmental impact.

“Oceanium is a European circular seaweed platform where sustainable sourcing and green processing meet science-backed nutrition,” Buchwald-Werner said on her appointment. “I was drawn to the company’s women-founded leadership, its commitment to planetary and human health, and its ambition to build safe, responsible solutions at scale. This is the kind of innovation our industry needs to align long-term health with environmental stewardship.”

For Oceanium, this appointment is anticipated to provide "deep expertise in guiding companies from scientific concept through responsible scale-up,” and her history of advising boards and investors across health tech and pharmaceuticals will support Oceanium’s expansion of its partnerships with global brands, the press release explains.

Aligning Science with Sustainability

The company’s proprietary, water-based processing methods support a portfolio spanning digestive health, skin health, and sustainable materials, Oceanium explains. By utilizing sustainably farmed seaweed, the company contributes to regenerative aquaculture and supports six UN Sustainable Development Goals.

Focusing on Gut Health: Ocean Actives H+

The board expansion coincides with the commercial acceleration of Ocean Actives H+, Oceanium’s seaweed-derived gut health ingredient. This ingredient is positioned as a solution for microbiome balance without bloating and digestive discomfort that can be associated with conventional prebiotics.

A trial conducted on the effects of the ingredient, “Gut Microbiome Modulation and Health Benefits of a Novel Fucoidan Extract from Saccharina latissima: A Double-Blind, Placebo-Controlled Trial,” was published in Microorganisms in June 2025.² For four weeks, ninety-one healthy participants ages were given capsules of a low dose of the extract, a high dose, or placebo twice daily. The results indicated a dose-dependent response, demonstrating increases in beneficial bacteria and short-chain fatty acid (SCFA) biosynthesis and carbohydrate metabolism.

Ocean Actives H+ is a brown seaweed Saccharina latissima extract, containing significant amounts of mixed fucoidan species, proteins, and polyphenols.

Future Outlook for Oceanium

Karen Scofield Seal, CEO and Co-Founder of Oceanium, said: “Dr. Buchwald-Werner is widely recognized for her scientific credibility, commercial insight and principled leadership. Her decision to join our Board is a strong endorsement of both our science and our long-term vision. As we scale Ocean Actives H+ internationally, her guidance will be invaluable in ensuring we grow with discipline, clarity and impact.”

As part of an upcoming feature article on algal-derived ingredients, Nutritional Outlook recently conducted an interview with Buchwald-Werner.³ She explained her motivation to join the company, stating, “My board work is guided by the belief that science, people, and culture must evolve together. When aligned, they support healthy aging, human resilience, and confident leadership. I joined Oceanium’s board to help ensure the company scales with clarity and discipline—keeping science, sustainability, and long-term value creation at the center of its global growth,” she explained.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Oceanium. Dr. Sybille Buchwald-Werner joins OCEANIUM Board. Press release provided via email January 27, 2026. Accessed February 27, 2026.
2. McEvoy, E. Brown seaweed-derived prebiotic shows gut health benefits without bloating, clinical trial finds. Published September 26, 2026. Accessed February 27, 2026.https://www.nutritionaloutlook.com/view/brown-seaweed-derived-prebiotic-shows-gut-health-benefits-without-bloating-clinical-trial-finds
3. McEvoy, E. Seaweed as a Platform: Sybille Buchwald-Werner, PhD, on Building Long-Term Resilience in Nutraceuticals. Published February 25, 2026. Accessed February 27, 2026. https://www.nutritionaloutlook.com/view/seaweed-as-a-platform-sybille-buchwald-werner-phd-on-building-long-term-resilience-in-nutraceuticals